liposome-based vaccine adjuvant ME-F-1051 (VesiVax®) vaccine adjuvant Pubmed:28922045 Vaccine adjuvant based on VesiVax® liposome. Pubmed:21545821 Gary Fujii vaccine adjuvant https://github.com/vaccineontology/VO/issues/784 VAC: https://vac.niaid.nih.gov/view?id=104 Pubmed:29420901 Pubmed:3568049 104 ME-F-1051 Chemical Nature: VesiVax® liposome Mechanism of Action: none Immune profile induced: none Route of immunization: SQ prime and IN boost, SQ, Combination sub-cheek, IN and ID, IN prime and sub-cheek boosts Point of Contact: Gary Fujii, Molecular Express Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=16713037 https://www.ncbi.nlm.nih.gov/pubmed/?term=17981684 https://www.ncbi.nlm.nih.gov/pubmed/?term=19835825 https://www.ncbi.nlm.nih.gov/pubmed/?term=21545821 https://www.ncbi.nlm.nih.gov/pubmed/?term=23313243 https://www.ncbi.nlm.nih.gov/pubmed/?term=26312747 https://www.ncbi.nlm.nih.gov/pubmed/?term=27997339 https://www.ncbi.nlm.nih.gov/pubmed/?term=28922045 https://www.ncbi.nlm.nih.gov/pubmed/?term=29420901 https://www.ncbi.nlm.nih.gov/pubmed/?term=3568049 Ongoing clinical trials: none Pubmed:19835825 ME-F-1051 (VesiVax®) Molecular Express Pubmed:27997339 Pubmed:23313243 https://violinet.org/vaxjo/vaxjo_detail.php?c_vaxjo_id=472 Pubmed:26312747 Pubmed:16713037 Jie Zheng